TaiMed Biologics (4147) reported revenue of NT$52.4 million for Oct 2026, +35.7% year on year and -2.7% from the previous month. Revenue for Jan–Oct 2026 was NT$552.4 million (+10.5% year on year).
In Oct 2026, it ranked No. 98 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$52.4 million | +35.7% | -2.7% |
| Sep 2026 | NT$53.9 million | -9.1% | -10.9% |
| Aug 2026 | NT$60.5 million | +19.5% | -5.1% |
| Jul 2026 | NT$63.7 million | +68.4% | +40.7% |
| Jun 2026 | NT$45.3 million | -16.9% | -28.6% |
| May 2026 | NT$63.3 million | +42.9% | +34.1% |
| Apr 2026 | NT$47.2 million | +21.8% | -39.8% |
| Mar 2026 | NT$78.4 million | +0.5% | +57.6% |
| Feb 2026 | NT$49.8 million | +2.9% | +31.4% |
| Jan 2026 | NT$37.9 million | -24.0% | -48.3% |
| Dec 2025 | NT$73.3 million | +56.9% | +93.3% |
| Nov 2025 | NT$37.9 million | -33.7% | -1.9% |
| Oct 2025 | NT$38.6 million | -7.5% | -34.8% |
| Sep 2025 | NT$59.2 million | +35.0% | +17.1% |
| Aug 2025 | NT$50.6 million | +0.6% | +33.8% |
| Jul 2025 | NT$37.8 million | -14.6% | -30.5% |
| Jun 2025 | NT$54.5 million | +23.8% | +22.9% |
| May 2025 | NT$44.3 million | -3.1% | +14.3% |
| Apr 2025 | NT$38.8 million | -32.2% | -50.3% |
| Mar 2025 | NT$78 million | +3.6% | +61.3% |
| Feb 2025 | NT$48.4 million | -19.0% | -2.9% |
| Jan 2025 | NT$49.8 million | +13.6% | +6.6% |
| Dec 2024 | NT$46.7 million | -20.5% | -18.3% |
| Nov 2024 | NT$57.2 million | +1.4% | +37.0% |
| Oct 2024 | NT$41.8 million | -2.7% | -4.8% |
Jan–Oct 2026 cumulative: NT$552.4 million (+10.5% YoY)
Other Biotech & Medical companies
Compare with peers: TaiMed Biologics vs PEC / TaiMed Biologics vs Lotus Pharm / TaiMed Biologics vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
每月營收受行銷夥伴每月進貨數量及CDMO生產時程影響而會有波動,但公司仍持續朝整年銷售目標前進
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16